logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Tumor mutational burden as biomarker of ICI benefit in NSCLC

Phase 3 MYSTIC data also support PD-L1 expression as a marker for OS.